In commercial lyophilized ADC drug product manufacturing for intravenous oncology infusion, the bulk drug substance is concentrated by ultrafiltration on a 30 kDa regenerated cellulose membrane and diafiltered against 5–8 volumes of pre-cooled formulation buffer containing 10–25 mM L-histidine at pH 5.0–6.5. Trehalose dihydrate is then added to achieve a lyoprotectant-to-protein mass ratio between 1:1 and 3:1, and polysorbate 80 is introduced at 0.01–0.1% w/v after final diafiltration to prevent surfactant loss in permeate. The resulting bulk formulation, typically at 5–20 mg/mL antibody-equivalent concentration, is passed through a 0.45 µm PVDF guard filter and a 0.22 µm PVDF or PES sterilizing filter before aseptic filling into USP Type I borosilicate glass vials conforming to ISO 8362-1 under EU GMP Annex 1 (2022) Grade A unidirectional airflow with Grade B background. During freezing, uncontrolled nucleation generates heterogeneous ice crystal size distributions that increase product resistance and primary drying time; an annealing step at -10°C to -25°C for 2–4 hours is therefore applied before primary drying at shelf temperature -25°C to -15°C and chamber pressure 100–200 mTorr, followed by secondary drying at 25–35°C for 6–12 hours until residual moisture measured by Karl Fischer titration remains below 3% w/w. In-process release under USP <1> and USP <787> includes visible and subvisible particle enumeration, container closure integrity per USP <1207>, and sterility per FDA 21 CFR 610.12. Terminal finished product types are sterile lyophilized cakes in single-dose vials of 50 mg, 100 mg, 160 mg, and 180 mg ADC payload-equivalent mass, reconstituted to 5 mg/mL, 10 mg/mL, or 20 mg/mL with sterile water for injection or 0.9% sodium chloride injection before further dilution for intravenous infusion. Tablet, capsule, and granule presentations are not established for intact monoclonal antibody-based ADCs; molecular weight above 150 kDa, gastrointestinal peptidase activity, and negligible paracellular transport preclude oral bioavailability, so downstream formulation work remains restricted to sterile injectable presentations.

What Limits Subvisible Particle Load During Sterile Filtration of ADC Formulations?

Subvisible particulate load in liquid ADC concentrates is controlled under USP <787> for therapeutic protein injections, with orthogonal methods using light obscuration and membrane microscopy for particles at ≥10 µm and ≥25 µm; the formulation path is designed to keep monomer purity above 95% by size-exclusion chromatography and to limit aggregate content below 5%. Liquid ADC drug product is formulated in 10–25 mM L-histidine or 10–20 mM potassium phosphate buffer at pH 5.0–6.5, with trehalose or sucrose added at 6–10% w/v and polysorbate 20 or polysorbate 80 at 0.01–0.04% w/v, producing a concentrate of 5–20 mg/mL antibody-equivalent material. The sterile filtration unit operation is executed with a 0.45 µm PVDF pre-filter followed by a 0.22 µm PVDF or PES sterilizing-grade membrane rated under ASTM F838-20; differential pressure across the sterilizing filter is kept below 0.8 bar to reduce shear-induced protein aggregation and to avoid particle shedding from the membrane. Downstream filling into 5 mL or 10 mL USP Type I vials is performed on aseptic lines equipped with rotary piston pumps and machine vision inspection for visible particulates under USP <790>. The terminal finished product types are preservative-free ready-to-dilute liquid vials, typically 50 mg/10 mL, 100 mg/5 mL, or 160 mg/8 mL, intended for further dilution in 0.9% sodium chloride injection or 5% dextrose injection; no tableting, encapsulation, or granulation step is used because the drug substance is a high-molecular-weight protein conjugate with cytotoxic payload chemistry that is incompatible with oral solid processing conditions and gastrointestinal degradation.

Low-volume aseptic filling of liquid ADC drug product on ceramic rotary piston pump lines is bounded by shear-rate constraints that are evaluated through post-fill subvisible particle counts and size-exclusion chromatography for aggregate formation. The filling formulation uses ADC drug substance at 5–10 mg/mL, L-histidine buffer at 10–20 mM pH 5.2–5.7, trehalose at 8% w/v, and polysorbate 80 at 0.02% w/v; nitrogen overlay maintains dissolved oxygen below 2 ppm during the holding period. The filling line operates in an ISO 5 isolator or restricted access barrier system with Grade B background, and fill weight is verified by in-process 100% checkweighing to a target volume of 5.0 mL ± 0.15 mL. Stopper insertion is performed under vacuum after flushing with sterile nitrogen, and residual moisture in the headspace is controlled to prevent vial cap corrosion and rubber stopper leachables. Container closure integrity is tested by vacuum decay per USP <1207>, and environmental monitoring follows EU GMP Annex 1 (2022) microbial limits below 1 CFU/m3 in Grade A settle plates. Terminal finished product types are sealed single-dose liquid vials with 50 mg or 100 mg ADC payload-equivalent content for intravenous infusion after dilution. The same line is not used for oral granulation or tablet compression because the ADC molecule undergoes aggregation and payload-linker cleavage under the moisture and temperature conditions of wet granulation and tableting.

When Ready-to-Use Liquid Vials Replace Lyophilized Presentation in Regional Oncology Distribution

Selection of a ready-to-use liquid vial over a lyophilized presentation changes the stability-limiting degradation pathways for ADC drug product, shifting emphasis from cake collapse and residual moisture to hydrolytic deconjugation of the payload-linker and polysorbate autooxidation in aqueous solution. Regulatory stability assessment is conducted under ICH Q5C and ICH Q1A(R2), with forced degradation studies examining pH 4.0–7.0, temperature 25–40°C, and oxidative stress; acceptance criteria are linked to USP <787> and USP <790> for particle control and to SEC monomer purity above 95%. The liquid formulation addition ratio for this presentation is typically ADC at 5–20 mg/mL, L-histidine buffer at 10–20 mM pH 5.2–5.5, trehalose or sucrose at 8–10% w/v, polysorbate 80 at 0.02% w/v, and optionally 0.1–0.5 mg/mL L-methionine as an antioxidant. Aseptic filling and stoppering are performed under nitrogen overlay with residual oxygen below 5% in headspace, followed by 100% visual inspection and container closure integrity testing by dye ingress or vacuum decay per USP <1207>. The terminal finished product type is a ready-to-dilute liquid injection, commonly 100 mg/20 mL or 160 mg/20 mL, stored at 2–8°C and protected from light; cold-chain exposure above 25°C for more than 24 hours triggers product-specific stability assessment. Oral tablet, capsule, and granule forms remain excluded for the intact conjugate because the immunoglobulin framework denatures in gastric fluid at pH below 3.5 and the released cytotoxic payload would require separate small-molecule oral development rather than ADC drug product manufacture.

Intravenous Infusion Bag Stability of ADC Diluents in Oncology Pharmacy

Intravenous infusion bag stability of ADC diluents in oncology pharmacy compounding is governed by USP <797> for sterile preparations, USP <800> for hazardous drug handling, and product-specific package insert limits that typically restrict diluted storage to 24 hours at 2–8°C followed by no more than 4 hours at ambient temperature unless otherwise authorized. The dilution process starts from a vial concentration of 5 mg/mL, 10 mg/mL, or 20 mg/mL and reduces the ADC to 1–5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection using polyvinyl chloride, polyolefin, or polyethylene infusion bags; in-line filters are 0.2 µm low-protein-binding polyethersulfone or polysulfone to avoid adsorptive loss above 10% of the diluted ADC mass. Compounding is performed in a biological safety cabinet with closed-system transfer devices to contain cytotoxic payloads, and the prepared admixture is inspected for visible particulates, discoloration, and bag integrity before transport to the patient area. Terminal finished product types are patient-specific intravenous infusion admixtures of 100–500 mL total volume; no terminal sterilization is applied after dilution, and the preparation is used within the in-use window because polysorbate 80 micelle destabilization and dilute protein concentration increase aggregation risk over time. Published data for specific ADC configurations is limited, but general practice excludes glass-admixed bottles, vigorous agitation, and freezing of the diluted product because ice-induced protein denaturation increases subvisible particle load above USP <787> limits.

Controlled Thaw and Pooling Parameters Govern Frozen ADC Drug Substance Transfer at CDMO Sites

At CDMO fill-finish sites, frozen ADC drug substance transfer between conjugation facilities and aseptic filling lines is governed by ICH Q5C stability principles and USP <1079> for storage and distribution, with frozen storage at -70°C to -80°C in single-use bags of 1 L, 5 L, and 10 L nominal volume. The frozen drug substance is formulated at 10–20 mg/mL ADC concentration in 10–20 mM L-histidine pH 5.2–5.5 with trehalose at 8% w/v and polysorbate 80 at 0.02% w/v; controlled thawing is executed in a 2–8°C cold room or jacketed single-use mixing vessel with wall temperature not exceeding 20°C, and pooling of multiple bags is completed within 12 hours under Grade C environment with sealed disposable connectors. The thawed pool is filtered through a 0.45 µm guard filter before final formulation adjustment and 0.22 µm sterilizing-grade filtration at the fill site, with tangential flow filtration used only if concentration above 20 mg/mL is required for filling high-dose presentations. Terminal finished product types from this intermediate are subsequent lyophilized or liquid injectable vials, while the frozen drug substance itself is released as a controlled intermediate under predefined specifications for DAR, free payload content, monomer purity above 95%, subvisible particles, endotoxin below 0.5 EU/mg, and bioburden below 10 CFU/10 mL. Tablet, capsule, and granule manufacturing units do not receive this material because the subsequent unit operations are incompatible with solid oral dosage processing.